# A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics

Source: https://onco.cc/ideas/idea-moon-brain-delivery-platform/  
OnCo record `idea-moon-brain-delivery-platform` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most cancer drugs cannot cross into the brain. Combine ultrasound that briefly opens the barrier with drugs engineered to be carried across, and make this a standard platform for every brain tumour and brain metastasis.

## Summary

The blood-brain barrier excludes most antibodies and many small molecules, limiting therapy for glioblastoma and brain metastases from lung, breast and melanoma. Focused ultrasound with microbubbles transiently opens the barrier and has delivered chemotherapy and antibodies in early trials; receptor-mediated shuttles (transferrin receptor) carry biologics across in neurology. The proposal is a platform programme: standardised ultrasound protocols and devices, a library of shuttle-enabled versions of active cancer drugs (antibody-drug conjugates, checkpoint inhibitors, bispecifics), pharmacokinetic validation in humans, and a trial network to test them in brain tumours and metastases.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Platform-enabled delivery raises intratumoural drug concentrations at least fivefold and improves intracranial progression-free survival in at least two indications within eight years.
- Rationale: Many drugs that work systemically fail intracranially for delivery, not biology; a solved delivery platform unlocks the existing armamentarium rather than requiring new drugs.
- Proposed test: Phase 1/2 studies with drug-level measurement in resected tissue after ultrasound or shuttle delivery, followed by randomised intracranial efficacy trials in HER2-positive breast cancer brain metastases and glioblastoma.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005): https://doi.org/10.1056/NEJMoa043330

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Focused ultrasound & histotripsy](https://onco.cc/technologies/hifu-histotripsy/)
- companies: [Insightec](https://onco.cc/companies/insightec/)
- bottlenecks: [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/), [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-brain-delivery-platform.json